BioPharma Resources

Drug Trial Radar · NCT07740564

Phase III Study of OT202 in Treating Moderate to Severe Dry Eye

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of OT202 Eye Drops in the Treatment of Moderate to Severe Dry Eye

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 842 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

842

Planned (sponsor's estimate)

Start

Aug 25, 2026

Primary completion

Jan 2029

Study completion May 2029

Sponsor

Sponsor type
Industry
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial, enrolling 842 subjects with moderate to severe dry eye, who will be randomized at a 1:1 ratio to receive either 1% OT202 ophthalmic solution or vehicle control. The trial consists of screening, run-in, 8-week double-blind treatment period, and three long-term safety follow-up cohorts (10 weeks, 28 weeks, and 54 weeks), including 342 subjects for the 10-week follow-up, 350 subjects for the 28-week follow-up, and 150 subjects for the 54-week follow-up. Unblinding will be performed after the completion of double-blind treatment for all subjects, who will then receive open-label 1% OT202 ophthalmic solution uniformly. The co-primary efficacy endpoints are the change from baseline in Total Corneal Fluorescein Staining Score (TCSS) and Visual Analog Scale-Eye Dryness Score (VAS-EDS) at Day 56. Pharmacokinetic assessments will be conducted in 60 of the subjects assigned to the 54-weeks long-term safety follow-up. An interim futility analysis will be performed once approximately 30% of subjects complete the treatment period. Analysis of covariance (ANCOVA) will be utilized for efficacy statistical analyses. The primary objective is to evaluate the efficacy and safety of OT202 ophthalmic solution in the treatment of moderate to severe dry eye.

Conditions

  • Dry Eye

Interventions

  • OT202 conc 1%Drug

    Apply 1-2 drops of OT202 1% solution into the conjunctival sac. three times daily

  • PlaceboDrug

    Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Corneal Fluorescein Staining (TCSS) scoreTime frame: Day 56
  2. Total visual analogue scale (VAS)-eye dryness score (EDS) scoreTime frame: Day 56

Locations

49 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Not yet recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chongqing Aier Eye Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Not yet recruiting

  • Xiamen Eye Center Affiliated to Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong

    Shantou, Guangdong, China · Not yet recruiting

  • Shenzhen Eye Hospital

    Shenzhen, Guangdong, China · Not yet recruiting

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

    Guiyang, Guizhou, China · Not yet recruiting

  • Hainan Eye Hospital of Zhongshan Ophthalmic Center, Sun Yat-sen University

    Haikou, Hainan, China · Not yet recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Harbin No.242 Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • Zhengzhou Second Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Changsha Aier Eye Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Changzhou Third People's Hospital

    Changzhou, Jiangsu, China · Not yet recruiting

  • Nanjing Medical University Eye Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The First People's Hospital of Xuzhou

    Xuzhou, Jiangsu, China · Not yet recruiting

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China · Not yet recruiting

  • Yanbian University Hospital

    Yanji, Jilin, China · Not yet recruiting

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China · Not yet recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The Fourth People's Hospital of Shenyang

    Shenyang, Liaoning, China · Not yet recruiting

  • People's Hospital of Ningxia Hui Autonomous Region

    Yinchuan, Ningxia, China · Not yet recruiting

  • Xi'an NO.1 Hospital

    Xi'an, Shaanxi, China · Not yet recruiting

  • Xi'an People's Hospital (Xi'an Fourth Hospital

    Xi'an, Shaanxi, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Not yet recruiting

  • Qingdao Eye Hospital of Shandong First Medical University

    Qingdao, Shandong, China · Not yet recruiting

  • Weifang Eye Hospital

    Weifang, Shandong, China · Not yet recruiting

  • Shanghai Eye Disease Prevention and Treatment Center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.